Concurrent chemoradiotherapy using cisplatin plus s-1, an oral fluoropyrimidine, followed by surgery for selected patients with stage III non-small cell lung cancer: A single-center feasibility study

Maruyama, Riichiroh; Hirai, Fumihiko; Ondo, Kaoru; Kometani, Takuro; Hamatake, Motoharu; Seto, Takashi; Sugio, Kenji; Ichinose, Yukito

doi:10.1007/s00595-011-4509-z

Cited by 10 publications

(3 citation statements)

References 14 publications

(16 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sudo et al [25] reported that CCRT with S-1 showed a promising antitumor effect, with a response rate of 41% and an MST of 16.8 months with acceptable toxicity in patients with locally advanced pancreatic cancer. CCRT with S-1 plus cisplatin for locally advanced non-small cell lung cancer has shown promising efficacy outcomes of 86.4-87.5% combined with good survival rates (24.4-33.1 months) and mild toxicity [26,27]. Likewise, CCRT with S-1 plus cisplatin for head and neck cancer is expected [28].…”

Section: Discussionmentioning

confidence: 99%

“…Recently, clinical studies of CCRT with S-1 for locally advanced pancreatic cancer [25] and CRT with S-1 plus cisplatin for non-small cell lung cancer [26,27], and head and neck cancer [28] have been attempted. Sudo et al [25] reported that CCRT with S-1 showed a promising antitumor effect, with a response rate of 41% and an MST of 16.8 months with acceptable toxicity in patients with locally advanced pancreatic cancer.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Concurrent Chemoradiotherapy with a Novel Fluoropyrimidine, S-1, and Cisplatin for Locally Advanced Esophageal Cancer: Long-Term Results of a Phase II Trial

Iwase¹,

Shimada²,

Tsuzuki³

et al. 2013

Oncology

View full text Add to dashboard Cite

Objectives: A phase II study was performed to investigate the safety and efficacy of concurrent chemoradiotherapy (CCRT) combined with an orally active fluoropyrimidine, S-1, plus cisplatin for locally advanced esophageal cancer (LAEC). Methods: CCRT comprised 2 courses, a 30-Gy radiotherapy over 3 weeks plus daily oral S-1 (80 mg/m²/day) for 2 weeks and a 24-hour cisplatin infusion (70 mg/m²) on day 8, and an identical course administered after a 2-week break. Results: One hundred and sixteen patients, 12 with stage II, 71 with stage III, and 33 with stage IVa LAEC participated, and 106 of them (91.4%) completed the CCRT course. The most serious toxicity was myelosuppression: grade 3 and 4 neutropenia occurred in 28.4 and 9.5% of patients, respectively. Nonhematologic toxicity was moderate. Complete response rates in patients with stage II, III, and IVa LAEC were 91.7, 67.6, and 36.4%, respectively. The overall median survival time was 2.3 years and that of patients with stage II, III, and IVa cancer was 7.0, 2.6, and 1.3 years, respectively. Conclusions: CCRT combined with S-1 plus cisplatin showed promising safety and efficacy. Potentially, this combination therapy could become a baseline medication for patients with LAEC.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Concurrent Chemoradiotherapy with a Novel Fluoropyrimidine, S-1, and Cisplatin for Locally Advanced Esophageal Cancer: Long-Term Results of a Phase II Trial

Iwase¹,

Shimada²,

Tsuzuki³

et al. 2013

Oncology

View full text Add to dashboard Cite

show abstract

“…In patients with marginally resectable stage III NSCLC, a small phase II trial has also reported that the safety and efficacy of induction treatment using S-1 plus CDDP and concurrent TRT and surgical resection was a feasible and promising new treatment modality [Maruyama et al 2011].…”

Section: Chemoradiotherapy Containing S-1 For Locally Advanced Nsclcmentioning

confidence: 99%

Clinical development of S-1 for non-small cell lung cancer: a Japanese perspective

Takeda

2013

Ther Adv Med Oncol

View full text Add to dashboard Cite

For more than a decade, S-1 has been investigated aggressively against non-small cell lung cancer (NSCLC) in Japan. Recently, two randomized phase III trials of S-1 combined with cisplatin (CDDP) or carboplatin (CBDCA) compared with the standard platinum doublet chemotherapy were reported. S-1 and CDDP was noninferior to CDDP and DTX in terms of overall survival (OS) (median survival time [MST] 16.1 versus 17.1 months, respectively; hazard ratio [HR] 1.013; 96.4% confidence interval [CI] 0.837-1.227). Noninferiority of S-1 and CBDCA compared with CBDCA and paclitaxel was also confirmed for OS (MST 15.2 versus 13.3 months, respectively; HR 0.928; 99.2% CI 0.671-1.283). The noninferiority design employed an upper CI limit of HR<1.322 in the former trial and HR<1.33 in the latter. S-1 combined with CDDP or CBDCA was thought to be one of the standard platinum doublet regimens in the first-line setting for patients with advanced NSCLC in Japan. Some additional interesting phase I and II studies have been published in Japan. They include studies of S-1 as first-line chemotherapy when combined with nonplatinum agents; as second-line chemotherapy; within chemoradiotherapy for locally advanced disease; and in the postoperative adjuvant setting. This review will also describe the use of S-1 for the treatment of NSCLC in these settings.

show abstract

Successful lung autotransplantation for central non-small-cell lung cancer: report of a case

et al. 2012

View full text Add to dashboard Cite

Non-small-cell lung cancer (NSCLC) confined to the lung is generally treated by surgical resection. The extent of resection is determined by the location of the tumor and the patient's pulmonary function. This report presents a successful lung autotransplantation in a man with NSCLC that could not tolerate pneumonectomy or sleeve lobectomy. Right upper and middle bilobectomies were performed, the right lower lobe was resected and retrograde perfusion of Raffinose low-potassium dextran solution (4 °C) was administered. The isolated lower lobe was reimplanted by anastomosis of the bronchus, pulmonary artery, and vein. The patient was cancer-free 1 year after the surgery. Lung autotransplantation can therefore be successfully performed for selected patients with central NSCLC.

show abstract

Concurrent chemoradiotherapy using cisplatin plus s-1, an oral fluoropyrimidine, followed by surgery for selected patients with stage III non-small cell lung cancer: A single-center feasibility study

Abstract: Induction treatment using S-1 plus cisplatin and concurrent radiotherapy and surgical resection for selected patients with stage III NSCLC is a feasible and promising new treatment modality.

Cited by 10 publications

References 14 publications

Concurrent Chemoradiotherapy with a Novel Fluoropyrimidine, S-1, and Cisplatin for Locally Advanced Esophageal Cancer: Long-Term Results of a Phase II Trial

Concurrent Chemoradiotherapy with a Novel Fluoropyrimidine, S-1, and Cisplatin for Locally Advanced Esophageal Cancer: Long-Term Results of a Phase II Trial

Clinical development of S-1 for non-small cell lung cancer: a Japanese perspective

Successful lung autotransplantation for central non-small-cell lung cancer: report of a case

Contact Info

Product

Resources

About